Divi's Lab.

Why is Divis Laboratories Ltd falling/rising?

As of 17-Aug, Divis Laboratories Ltd's stock price is at 8,495.00, reflecting a slight decline but strong performance over various time frames. Despite positive fundamentals and high management efficiency, concerns over valuation and decreased investor participation may be impacting the stock's current price movement.

As of 17-Aug, Divis Laboratories Ltd's stock price is currently at 8,495.00, reflecting a slight decline of 5.0 points or 0.06%. Despite this minor drop, the stock has shown strong performance over various time frames, with a 1-week increase of 2.66%, a 1-month rise of 17.04%, and a year-to-date gain of 32.85%. Additionally, the stock has outperformed the Sensex, which has declined by 1.04% over the past week and 0.54% over the past month.<BR><BR>The stock's current price is just 2.07% away from its 52-week high of Rs 8,670.5, indicating that it is trading near its peak. Furthermore, Divis Laboratories Ltd is performing well in comparison to its moving averages, trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day averages. This suggests a generally positive trend in the stock's performance.<BR><BR>However, there are some negative indicators contributing to the current price movement. Notably, there has been a decline in investor participation, with delivery volume dropping by 18.17% against the 5-day average. This decrease in trading activity may be influencing the stock's price stability.<BR><BR>On the positive side, the company has demonstrated high management efficiency with a return on equity (ROE) of 16.32% and is net-debt free. It has also reported positive results for the last eight consecutive quarters, with record figures in PBDIT and net sales. High institutional holdings at 39.58% further support the stock's stability, as these investors typically have better resources to analyze company fundamentals.<BR><BR>Despite these strengths, there are concerns regarding long-term growth, as net sales have only grown at an annual rate of 9.30% over the last five years. The stock is considered expensive with a price-to-book value of 13.5, which is higher than its peers' average historical valuations. This premium valuation, combined with a PEG ratio of 2.6, may be causing some investors to reassess their positions, contributing to the current price decline.<BR><BR>In summary, while Divis Laboratories Ltd has shown strong performance metrics and positive fundamentals, the recent drop in investor participation and concerns over valuation may be influencing the stock's current price movement.

Which are the latest news on Divi's Lab.?

Who are in the management team of Divi's Lab.?

The management team of Divi's Lab includes key members such as Murali K Divi (Chairman & Managing Director), Kiran S Divi (CEO), and several independent directors, all of whom guide the company's strategic direction and operations.

The management team of Divi's Lab includes the following key members:<BR><BR>1. **Murali K Divi** - Chairman & Managing Director<BR>2. **N V Ramana** - Executive Director<BR>3. **Madhusudana Rao Divi** - Whole Time Director (Projects)<BR>4. **Kiran S Divi** - Whole Time Director & CEO<BR>5. **Nilima Motaparti** - Whole Time Director - Commercial<BR>6. **G Suresh Kumar** - Independent Director<BR>7. **Ranga Rao Ravipati** - Independent Director<BR>8. **K V K Seshavataram** - Independent Director<BR>9. **Ramesh B V Nimmagadda** - Chairman (Non-Executive) & Independent Director<BR>10. **S Ganapaty** - Independent Director<BR>11. **Sunaina Singh** - Independent Director<BR>12. **Kosaraju Veerayya Chowdary** - Independent Director<BR>13. **Satish Choudhury** - Company Secretary & Compliance Officer<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

What does Divi's Lab. do?

Divi's Laboratories Limited is a prominent pharmaceutical company specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceuticals. As of June 2026, it reported net sales of ₹3,080 Cr and a net profit of ₹902 Cr, with a market capitalization of ₹224,799 Cr.

Overview:<BR>Divi's Laboratories Limited is a leading pharmaceutical company engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceuticals, operating within the Pharmaceuticals & Biotechnology industry and classified as a Large Cap company.<BR><BR>History:<BR>Divi's Laboratories was incorporated in the year 1990. The latest quarterly results reported are for June 2026, showcasing the company's ongoing operations.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 3,080 Cr (Quarterly Results - Jun 2026)<BR>- Most recent Net Profit: 902 Cr (Quarterly Results - Jun 2026)<BR>- Market-cap value: INR 224,799 Cr (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 76.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.35%<BR>- Debt-Equity: -0.20<BR>- Return on Equity: 15.65%<BR>- Price to Book: 13.53<BR><BR>Contact Details:<BR>Address: 1-72-23(P)/DIVIS/303 Divi Tower, Cyber Hills Gachibowli Hyderabad Telangana : 500032 <BR>Tel: 91-40-23786300/23786352/400 <BR>Email: mail@divislabs.com <BR>Website: http://www.divislaboratories.com

Who are the peers of the Divi's Lab.?

Divi's Lab. has peers including Sun Pharma, Torrent Pharma, Cipla, Zydus Lifesci, Lupin, Mankind Pharma, Laurus Labs, Dr Reddy's Labs, Aurobindo Pharma, and Biocon. In terms of returns, Laurus Labs leads with 113.22% over one year, while Divi's Lab. has a return of 39.27%.

Peers: Divi's Lab. has the following peers: Sun Pharma.Inds., Torrent Pharma, Cipla, Zydus Lifesci., Lupin, Mankind Pharma, Laurus Labs, Dr Reddy's Labs, Aurobindo Pharma, and Biocon.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Torrent Pharma, Cipla, Zydus Lifesci., Lupin, Mankind Pharma, Laurus Labs, Dr Reddy's Labs, and the rest. Below Average growth is found at Divi's Lab., Cipla, and Laurus Labs, while Average growth is noted at Torrent Pharma and Dr Reddy's Labs, and the rest exhibit Good or Excellent growth. Excellent capital structure is seen at Sun Pharma.Inds., Divi's Lab., Cipla, Zydus Lifesci., Mankind Pharma, Aurobindo Pharma, and the rest have Good or Average capital structures.<BR><BR>Return Snapshot: Laurus Labs has the highest 1-year return at 113.22%, while Cipla has the lowest at -6.46%. Divi's Lab.'s 1-year return of 39.27% is significantly higher than Cipla's but lower than Laurus Labs. Additionally, the peers with negative six-month returns include Lupin and Dr Reddy's Labs.

How big is Divi's Lab.?

As of 14th August, Divis Laboratories Ltd has a market capitalization of 226,311.96 Cr, with recent net sales of 11,230.00 Cr and net profit of 2,925.00 Cr over the last four quarters.

As of 14th August, <BR><BR>Market Cap: Divis Laboratories Ltd has a market capitalization of 226,311.96 Cr, categorizing it as a Large Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 11,230.00 Cr, while the sum of Net Profit for the same period is 2,925.00 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2026, with Shareholder's Funds amounting to 16,761.00 Cr and Total Assets totaling 20,019.00 Cr.

Are Divis Laboratories Ltd latest results good or bad?

Divi's Laboratories Ltd reported strong Q1 FY27 results, with net sales of ₹3,080 crores (up 27.80% year-on-year) and a net profit of ₹902 crores (up 65.50% year-on-year), indicating a positive performance and operational efficiency. Overall, the results are considered good for the company.

Divi's Laboratories Ltd has delivered strong results for Q1 FY27, indicating a positive performance overall. The company reported net sales of ₹3,080 crores, which reflects a significant year-on-year growth of 27.80% and an 8.80% increase compared to the previous quarter. This marks the highest quarterly revenue in the company's recent history.<BR><BR>The net profit for the quarter reached ₹902 crores, showing an impressive year-on-year increase of 65.50% and a sequential growth of 20.11%. Operating margins have also expanded dramatically to 40.75%, the highest in eight quarters, demonstrating the company's operational efficiency and pricing power in a competitive market.<BR><BR>Overall, the results indicate that Divi's Laboratories is effectively navigating the post-pandemic landscape and capitalizing on strong demand for its products. The stock has responded positively, with a notable rally in its price following the results announcement. This performance suggests that the latest results are indeed good for the company.

Should I buy, sell or hold Divis Laboratories Ltd?

When is the next results date for Divis Laboratories Ltd?

The next results date for Divis Laboratories Ltd is 23 May 2026.

The next results date for Divis Laboratories Ltd is scheduled for 23 May 2026.

Is Divi's Lab. technically bullish or bearish?

As of December 1, 2025, Divi's Lab shows a mildly bullish trend, supported by bullish weekly MACD and Bollinger Bands, despite mixed signals from monthly indicators.

As of 1 December 2025, the technical trend for Divi's Lab has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, supporting a positive outlook. Daily moving averages are bullish, reinforcing the mildly bullish stance. However, the KST shows a bullish weekly trend but is mildly bearish monthly, and Dow Theory indicates no clear trend on both weekly and monthly charts. Overall, the current technical stance is mildly bullish, driven by the weekly MACD and Bollinger Bands, despite some bearish signals on the monthly indicators.

How has been the historical performance of Divi's Lab.?

Divi's Lab has shown consistent growth in net sales and profitability, with net sales increasing from 4,946.26 Cr in Mar'19 to 9,360.00 Cr in Mar'25, and profit after tax rising to 2,191.00 Cr in Mar'25. The company's total assets also grew significantly, reflecting a strong financial performance overall.

Answer:<BR>The historical performance of Divi's Lab shows a consistent growth trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Divi's Lab has demonstrated a steady increase in net sales, rising from 4,946.26 Cr in Mar'19 to 9,360.00 Cr in Mar'25. The total operating income followed a similar trajectory, reaching 9,360.00 Cr in Mar'25, up from 7,767.00 Cr in Mar'23. Operating profit (PBDIT) also saw fluctuations, peaking at 3,995.81 Cr in Mar'22 before settling at 3,320.00 Cr in Mar'25. Profit before tax increased to 2,916.00 Cr in Mar'25 from 2,163.00 Cr in Mar'24, while profit after tax reached 2,191.00 Cr in Mar'25, up from 1,600.00 Cr in Mar'24. The company's total assets grew significantly from 8,531.32 Cr in Mar'20 to 16,921.00 Cr in Mar'25, reflecting a robust expansion. Total liabilities also increased, but at a slower pace, indicating a strengthening balance sheet. Cash flow from operating activities improved to 1,653.00 Cr in Mar'25, contributing to a net cash inflow of 50.00 Cr for the year. Overall, Divi's Lab has shown resilience and growth in its financial performance across multiple metrics.

Who are the top shareholders of the Divi's Lab.?

The top shareholders of Divi's Lab include promoter Nilima Prasad Divi with 20.34%, foreign institutional investors holding 18.01%, mutual funds at 12.83%, and the Life Insurance Corporation of India as the largest public shareholder with 5.63%. Individual investors own 7.17% of the shares.

The top shareholders of Divi's Lab include the promoters, who hold the majority of the shares. Notably, Nilima Prasad Divi is the promoter with the highest holding at 20.34%. In addition, foreign institutional investors (FIIs) hold 18.01% of the shares, while mutual funds collectively account for 12.83% through 39 schemes. The highest public shareholder is the Life Insurance Corporation of India, which holds 5.63%. Individual investors also have a stake, representing 7.17% of the total shares.

What is the bonus history of the Divi's Lab.?

Divi's Laboratories has a history of issuing bonus shares, with the most recent being a 1:1 bonus announced on September 23, 2015, and a prior 1:1 bonus on August 1, 2009. This reflects the company's consistent practice of rewarding shareholders.

Divi's Laboratories has a history of issuing bonuses. The most recent bonus was a 1:1 bonus issue, which was announced with an ex-date of September 23, 2015, and the record date was September 26, 2015. Prior to that, the company also issued a 1:1 bonus on August 1, 2009, with an ex-date of July 30, 2009. This indicates that Divi's Lab has a consistent practice of rewarding its shareholders through bonus shares.

Has Divi's Lab. declared dividend?

Divis Laboratories Ltd has declared a 1500% dividend, amounting to ₹30 per share, with an ex-date of August 2, 2024. The company has shown strong total returns over various periods, particularly with a 169.61% total return over the past five years.

Divis Laboratories Ltd has declared a 1500% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1500%<BR>- Amount per share: 30<BR>- Ex-date: 02 Aug 24<BR><BR>Dividend Yield: 0.45%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 5.9%, the dividend return was 0%, resulting in a total return of 5.9%.<BR><BR>Over the past year, the price return was 45.73%, the dividend return was 0.67%, leading to a total return of 46.4%.<BR><BR>In the 2-year period, the price return was 84.08%, the dividend return was 1.67%, culminating in a total return of 85.75%.<BR><BR>For the 3-year period, the price return was 85.98%, the dividend return was 2.50%, resulting in a total return of 88.48%.<BR><BR>In the last 4 years, the price return was 52.87%, the dividend return was 2.55%, leading to a total return of 55.42%.<BR><BR>Over the past 5 years, the price return was 164.6%, the dividend return was 5.01%, resulting in a total return of 169.61%.<BR><BR>Overall, Divis Laboratories Ltd has declared a significant dividend, and the total returns over various periods indicate strong performance, particularly in the long term, with substantial price appreciation and increasing dividend contributions.